



Presented by Infection Control Consultants of New Mexico



## Welcome

IC Nuggets of Knowledge Series are monthly one-hour learning sessions using a web-based format to share information, network, and opportunity to address questions and concerns with ICCNM Consultants

When: 1:00 to 2:00 pm

2nd Thursday of the month

If you have feedback on this learning opportunity or have suggestions for future learning opportunities, feel free to reach out to me at any time!

- ncostilla@tha.org

## Introductions

- Infection Control Consultants of NM (ICCNM Consulting)
- New Mexico based consulting company
- Consultants are certified in Infection Control (CIC)
- Presenters for this series
  - Kerry Flint, PhD
  - Terri Kangas-Feller
  - Barbara Mooney
- www.iccnm.org

# Healthcare Associated Infections

This Photo by Unknown author is licensed under CC BY-SA

## Session Outline

- Describe the impact of a pandemic on HAI.
- Identify tools to support front-line staff combat HAI.
- Discuss how we refocus on HAI in the current environment.

## The Problem

Each day, approximately one in 31 U.S. patients contracts at least one infection in association with his or her hospital care, underscoring the need for improvements in patient care practices in U.S. healthcare facilities.

CDC HAI Data

## Estimating the Cost

- CLABSI
  - Additional cost \$48,108 (95% CI: \$27,232 to \$68,983)
  - Excess mortality 0.15
- CAUTI
  - Additional Cost \$13,793 (95% CI: \$5,019 to \$22,568)
  - Excess mortality 0.036
- VAP
  - Additional Cost \$47,238 (95% CI: \$21,890 to \$72,587),
  - Excess mortality 0.14
- CDI
  - Additional Cost\$17,260 (95% CI: \$9,341 to \$25,180),
  - Excess mortality, 0.044

#### FINAL REPORT

Estimating the Additional Hospital Inpatient Cost and Mortality Associated With Selected Hospital-Acquired Conditions

#### PREPARED FOR: Agency for Healthcare Research and Quality 5600 Fishers Lane

Rockville, MD 20857 www.ahrq.gov

CONTRACT NO. HHSP233201500023I

AHRO Publication No. 18-0011-EF November 2017

Tyler Bysshe, MPH Yue Gao, MPH Krysta Heaney-Huls, MPH Jason Hockenberry, PhD Lauren Hovey, MA Alison M Laffan, PhD Suhna Lee, PhD, MPA David J Murphy, MD, PhD Elizabeth Watts, PhD, MPH

PREPARED BY:

Chicago

NORC at the University of



Estimating the Additional Hospital Inpatient Cost and Mortality Associated With Selected Hospital-Acquired Conditions Agency for Healthcare Research and Quality (ahra.gov)



## **Reporting Data**

- Impact of COVID-19 Pandemic
  - CMS implemented the extraordinary circumstance exception policy
  - Excused reporting via NHAN for 2019 Q4 through 2020 Q2
  - Approx 86% hospitals reported 2020 Q1 and Q2 data for CLABSI, CAUTI, MRSA bacteremia or CDI
  - VAP and SSI reporting greatest decline
  - Reporting improved in second half of 2022

## Impact of COVID-19

SHEA

Infection Control & Hospital Epidemiology (2022), 43, 12-25 doi:10.1017/ice.2021.362



#### The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: A summary of data reported to the National Healthcare Safety Network

Lindsey M. Weiner-Lastinger MPH<sup>1</sup> O, Vaishnavi Pattabiraman MSc, MS, MPH<sup>1,2</sup>, Rebecca Y. Konnor MPH<sup>1,3</sup>, Prachi R. Patel MPH<sup>1,3</sup>, Emily Wong MPH<sup>1,2</sup>, Sunny Y. Xu MPH<sup>1,3</sup>, Brittany Smith MPH<sup>1,4</sup>, Jonathan R. Edwards MStat<sup>1</sup> and Marearet A. Dudeck MPH<sup>1</sup>

<sup>1</sup>Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, <sup>2</sup>Leidos, Atlanta, Georgia, <sup>3</sup>CACI, Atlanta, Georgia and <sup>4</sup>Oak Ridge Institute of Science and Education, Oak Ridge, Tennessee

#### Abstract

Objectives: To determine the impact of the coronavirus disease 2019 (COVID-19) pandemic on healthcare-associated infection (HA1) incidence in US hospitals, national- and state-level standardized infection ratios (SIRs) were calculated for each quarter in 2020 and compared to those from 2019.

Methods: Central-line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilatorassociated events (VAEs), select surgical site infections, and *Clastritioides difficile* and methicillin-resistant *Staphylococcus aureus* (MRSA) hactermini laboratory-identified events reported to the National Healthicare Safety Network for 2019 and 2020 by acute-care hospitals were analyzed. SIRs were calculated for each HAI and quarter by dividing the number of reported infections by the number of predicted infections, calculated using 2015 national baseline data. Percentage changes between 2019 and 2020 SIRs were calculated. Supporting analyses, such as an assessment of device utilization in 2020 compared to 2019, were also performed.

Results: Significant increases in the national SIRs for CLABSI, CAUTI, VAE, and MRSA bacteremia were observed in 2020. Changes in the SIR varied by quarter and state. The largest increase was observed for CLABSI, and significant increases in VAE incidence and ventilator utilization were seen across all 4 quarters of 2020.

Conclusions: This report provides a national view of the increases in HAI incidence in 2020. These data highlight the need to return to conventional infection prevention and control practices and build resiliency in these programs to withstand future pandemics.

(Received 12 July 2021; accepted 15 July 2021; electronically published 3 September 2021)

Results: Significant increases in the national SIRs for CLABSI, CAUTI, VAE, and MRSA bacteremia were observed in 2020. Changes in the SIR varied by quarter and state. The largest increase was observed for CLABSI, and significant increases in VAE incidence and ventilator utilization were seen across all 4 quarters of 2020

## Current State - CDC

Between 2019 & 2020

## Reductions

- 11% decrease in hospital onset C. difficile infections
- 5% decrease in SSI, for 10 select procedures
  - Surgical Care Improvement Project (SCIP) procedures. About 9% decrease in abdominal hysterectomy SSIs
- About 5% decrease in colon surgery SSIs

## Increases

- 24% increase in CLABSI
  - Largest increase in ICU (50%)
- 35% increase in VAE
  - About 34% increase observed in ICU
  - About 60% increase observed in ward
- no significant change in CAUTI outside ICU
  - 10% increase observed in ICU

SIR

	2020 Q1	2020 Q2	2020 Q3	2020 Q4
CLABSI	-11.8%	27.9%	46.4%	47.0%
CAUTI	-21.3%	No Change <sup>1</sup>	12.7%	18.8%
VAE	11.3%	1 33.7%	<b>1</b> 29.0%	44.8%
SSI: Colon surgery	-9.1%	No Change <sup>1</sup>	-6.9%	-8.3%
SSI: Abdominal hysterectomy	-16.0%	No Change <sup>1</sup>	No Change <sup>1</sup>	-13.1%
Laboratory-identified MRSA bacteremia	-7.2%	12.2%	22.5%	133.8%
Laboratory-identified CDI	-17.5%	-10.3%	-8.8%	-5.5%

## Texas Data

Table 6. 2020 Q2 and Q3 Central-Line-Associated Bloodstream Infection (CLABSI)<sup>a</sup> Standardized Infection Ratios (SIRs) for Acute-Care Hospitals Compared to 2019 for Select States

	2020 Q2 vs 2019 Q2				2020 Q3 vs 2019 Q3									
State <sup>b</sup>	No. of Hospitals <sup>c</sup>	2020 Q2 No. of CLABSIs	2020 Q2 No. of Predicted CLABSIs	2020 Q2 SIR	2019 Q2 SIR	% Change <sup>d</sup> in SIR	95% CI Around SIR % Change	No. of Hospitals <sup>c</sup>	2020 Q3 No. of CLABSIs	2020 Q3 No. of Predicted CLABSIs	2020 Q3 SIR	2019 Q3 SIR	% Change <sup>d</sup> in SIR	95% CI Around SIR % Change
Arizona	59	80	82.63	0.97	0.39	148.7 <sup>e</sup>	(64.6-275.6)	59	105	92.20	1.14	0.46	147.8 <sup>e</sup>	(72.5–269.2)
California	300	309	358.57	0.86	0.61	41.0 <sup>e</sup>	(18.5-66.6)	323	536	436.18	1.23	0.70	75.7 <sup>e</sup>	(51.9–102.8)
Florida	189	166	241.80	0.69	0.72	-4.2	(–22.0 to 18.1)	207	381	312.59	1.22	0.62	96.8 <sup>e</sup>	(65.7–137.0)
Georgia	100	131	155.77	0.84	0.59	42.4 <sup>e</sup>	(9.4-86.5)	103	238	172.12	1.38	0.68	102.9 <sup>e</sup>	(61.7–156.6)
Illinois	111	129	126.73	1.02	0.69	47.8 <sup>e</sup>	(12.4–91.9)	129	111	166.12	0.67	0.68	-1.5	(-23.9 to 28.7)
Louisiana	65	47	39.87	1.18	0.69	71.0 <sup>e</sup>	(7.9–174.3)	85	101	69.75	1.45	0.89	62.9 <sup>e</sup>	(18.4–125.6)
Massachusetts	59	109	87.77	1.24	0.62	100.0 <sup>e</sup>	(45.1-181.7)	65	81	95.71	0.85	0.63	34.9	(-3.9 to 86.7)
Michigan	76	119	91.17	1.31	0.75	74.7 <sup>e</sup>	(29.6-136.3)	94	111	130.22	0.85	0.64	32.8 <sup>e</sup>	(0.1-77.2)
New Jersey	28	37	32.93	1.12	0.81	38.3	(–18.1 to 137.8)	67	76	88.38	0.86	0.54	59.3 <sup>e</sup>	(10.7–127.9)
New York	100	73	121.75	0.60	0.61	-1.6	(–29.4 to 34.9)	168	249	285.50	0.87	0.77	13.0	(-5.3 to 35.6)
Pennsylvania	156	222	215.55	1.03	0.77	33.8 <sup>e</sup>	(10.4-64.3)	155	197	234.26	0.84	0.80	5.0	(-13.7 to 29.2)
Texas	302	242	305.15	0.80	0.73	9.6	(-8.4 to 31.1)	322	487	395.20	1.23	0.73	68.5 <sup>e</sup>	(45.8–97.8)

Note. CI, confidence interval; CDC, Centers for Disease Control and Prevention; NHSN, National Healthcare safety Network; icu, intensive care unit.

<sup>a</sup>SIRs were calculated using data from adult and pediatric ICUs, neonatal ICUs, and adult and pediatric medical, surgical, and medical–surgical wards.

<sup>b</sup>Quarterly CLABSI SIRs are available for all eligible states and quarters in the Supplementary Tables (online). The states shown in this table were identified by the CDC as having a high number of hospitalized COVID-19 patients between April 1, 2020, and July 14, 2020.<sup>1</sup>

<sup>c</sup>Hospitals reporting complete CLABSI surveillance data to the NHSN for the same location for both quarters in the comparison.

<sup>d</sup>% change was calculated as follows: [(2020 SIR - 2019 SIR) ÷ 2019 SIR] × 100.

 $\boldsymbol{<}$ 

<sup>e</sup>Statistical significance based on 2-tailed  $P \leq .05$ , reflected in the relative % change in magnitude.

## TX HAI Plan

- **2**019 ~
  - 640 acute care hospitals,
  - 523 ambulatory surgery centers,
  - 216 free standing emergency medical centers.
- Increased AB stewardship Capacity
- Healthcare Safety Advisory Committee
- Surveillance and Response





## CLABSI

## Central Line Associated Blood Stream Infections

## Outcome Burden

- Increased LOS
- Increased cost of care
  - \$48,000 higher cost than those without CLABSI (2015 cost)
- Increased morbidity and mortality

## **Risk Factors**

#### ICU

- Frequent insertion of multiple catheters
- Catheters specific to ICU population
- Frequent access
- Long duration
- Hemodialysis
- Oncology (immune compromised)
- Intraoperative patients
- Prolonged hospitalization precatheterization
- Prolonged duration
- Microbial colonization
- Multiple lumens
- Concurrent catheters
- Neutropenia
- ► BMI >40
- Prematurity

- Nurse-patient ratios
- PN
- Substandard catheter care
- Blood transfusion in children



## **CLABSI** Prevention Strategies

## Essential Practices

- Should be adopted by all ACH
- Considered foundational prevention actions
- Previously referred to as basic practices
- Additional Approaches
  - Specific locations/populations
  - Uncontrolled CLASBI events after implementation of Essential Practices

Infection Control & Hospital Epidemiology (2022), 43, 553–569 doi:10.1017/ice.2022.87

#### **SHEA**

#### SHEA/IDSA/APIC Practice Recommendation

## Strategies to prevent central line-associated bloodstream infections in acute-care hospitals: 2022 Update

Niccolò Buetti MD, MSc, PhD<sup>1,2,a</sup> , Jonas Marschall MD, MSC<sup>3,4,a</sup> , Marci Drees MD, MS<sup>5,6</sup> , Mohamad G. Fakih MD, MPH<sup>7</sup> , Lynn Hadaway MEd, RN, NPD-BC, CRNI<sup>8</sup>, Lisa L. Maragakis MD, MPH<sup>9</sup>, Elizabeth Monsees PhD, MBA, RN, CIC<sup>10,11</sup> , Shannon Novosad MD MPH<sup>12</sup>, Naomi P. O'Grady MD<sup>13</sup>, Mark E. Rupp MD<sup>14</sup> , Joshua Wolf MBBS, PhD, FRACP<sup>15,16</sup> , Deborah Yokoe MD, MPH<sup>17</sup> and Leonard A. Mermel DO, ScM<sup>18,19</sup>

<sup>1</sup>Infection Control Programme, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland, <sup>1</sup>University of Paris, Paris, France, <sup>1</sup>Department of Infections Diseases, Bern University Hospital and University of Bern, Bern, Switzerland, <sup>1</sup>Univison of Infections Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States, <sup>1</sup>ChristianaCare, Wilmington, Delaware, United States, <sup>1</sup>Sidney Kimmel Medical College at Thomas Jefferson University, Philadehina, Pennsylvania, United States, <sup>1</sup>Schersion Healthcare and Wayne State University School of Medicine, Detroit, Michigan, University School of Medicine, Baroty, Missouri, United States, <sup>1</sup>Johns Hopkins University School of Medicine, Bartori, Michigan, Unived States, <sup>1</sup>Uynn Hadaway Associates, Miner, Georgia, United States, <sup>1</sup>Johns Hopkins University School of Medicine, Bartori, Michigan, Unived States, <sup>1</sup>Uynn Hadaway Associates, Miner, Georgia, United States, <sup>1</sup>Johns Hopkins University of Missouri-Kanasa City School of Medicine, Ransas City, Missouri, United States, <sup>11</sup>University of Hassina Care, <sup>11</sup>University of Hassina, Lance, <u>Borgia, United States, <sup>11</sup>University of Health</u>, Bethesda, Manyland, United States, <sup>31</sup>University of Nebraska Medical Center, Omaha, Nebraska, United States, <sup>11</sup>Dopartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, United States, <sup>11</sup>Department of Paris, University of Tennessee Health Science Center, Memphis, Tennessee, United States and <sup>11</sup>Bihode Haand Hospital, Providence, Rinde States, <sup>11</sup>Warren Alpert Medical School of Brown University.

## **SHEA Essential Practices**

#### **Essential Practices**

Before insertion

- 1. Provide easy access to an evidence-based list of indications for CVC use to minimize unnecessary CVC placement (Quality of Evidence: LOW)
- Require education and competency assessment of HCP involved in insertion, care, and maintenance of CVCs about CLABSI prevention (Quality of Evidence: MODERATE)<sup>74-78</sup>
- 3. Bathe ICU patients aged >2 months with a chlorhexidine preparation on a daily basis (Quality of Evidence: HIGH)<sup>86-90</sup>
- At insertion
- In ICU and non-ICU settings, a facility should have a process in place, such as a checklist, to ensure adherence to infection prevention practices at the time of CVC insertion (Quality of Evidence: MODERATE)<sup>101</sup>
- 2. Perform hand hygiene prior to catheter insertion or manipulation (Quality of Evidence: MODERATE)<sup>102-107</sup>
- 3. The subclavian site is preferred to reduce infectious complications when the catheter is placed in the ICU setting (Quality of Evidence: HIGH)<sup>33,37,108-110</sup>
- 4. Use an all-inclusive catheter cart or kit (Quality of Evidence: MODERATE)<sup>118</sup>
- 5. Use ultrasound guidance for catheter insertion (Quality of Evidence: HIGH)<sup>119,120</sup>
- 6. Use maximum sterile barrier precautions during CVC insertion (Quality of Evidence: MODERATE)<sup>123-128</sup>
- 7. Use an alcoholic chlorhexidine antiseptic for skin preparation (Quality of Evidence: HIGH)<sup>42,129-134</sup> After insertion
- 1. Ensure appropriate nurse-to-patient ratio and limit use of float nurses in ICUs (Quality of Evidence: HIGH)<sup>34,35</sup>
- 2. Use chlorhexidine-containing dressings for CVCs in patients over 2 months of age (Quality of Evidence: HIGH)<sup>45,135-142</sup>
- 3. For non-tunneled CVCs in adults and children, change transparent dressings and perform site care with a chlorhexidine-based antiseptic at least every 7 days or immediately if the dressing is soiled, loose, or damp. Change gauze dressings every 2 days or earlier if the dressing is soiled, loose, or damp (Quality of Evidence: MODERATE)<sup>145-148</sup>
- 4. Disinfect catheter hubs, needleless connectors, and injection ports before accessing the catheter (Quality of Evidence: MODERATE)<sup>150-154</sup>
- 5. Remove nonessential catheters (Quality of Evidence: MODERATE)
- Routine replacement of administration sets not used for blood, blood products, or lipid formulations can be performed at intervals up to 7 days (Quality of Evidence: HIGH)<sup>164</sup>
- 7. Perform surveillance for CLABSI in ICU and non-ICU settings (Quality of Evidence: HIGH)<sup>13,165,166</sup>

## INS Standards – 8<sup>th</sup> edition Revised 2021

11. Adverse and Serious

Adverse Events

- Section 3: Infection Prevention & Control (Standards 53-60)
  - Hand Hygiene
  - Standard Precautions
  - Aseptic Non Touch Technique
  - Transmission Based Precautions
  - Compounding and Preparation of Parental Solutions and Medications
  - Medical Waste and Sharps Safety
- New filtration recommendations (Impacts Standard 35 and 63)

Note: T	he "S" in p	age numbers denotes supplement issue and does not	refer to	a specific
Foreword	<b>S1</b>	12. Product Evaluation,		2
About the Standards of Practice Committee	\$3	Integrity, and Defect Reporting	S45	2
Author Disclosures and		13. Medication Verification	S46	2
Acknowledgments	S6	14. Latex Sensitivity or Allergy	S49	
Preface	S7	15. Hazardous Drugs and	CEO	3
Methodology for Developing the Standards of Practice	S8	SECTION THREE	330	3
Abbreviations and Acronyms	S10	INFECTION PREVENTION	NC	3
Strength of the Body of Evidence	S12	AND CONTROL		
STANDARDS OF PRACTI		16. Hand Hygiene	\$53	
		17. Standard Precautions	S54	3
THERAPY PRACTICE	ION	<ol> <li>Aseptic Non Touch Technique (ANTT<sup>®</sup>)</li> </ol>	\$56	3
1. Patient Care	S13	<ol> <li>Transmission-Based Precautions</li> </ol>	S58	
<ol> <li>Special Patient Populations: Neonatal, Pediatric, Pregnant, and Older Adults</li> </ol>	S13	20. Compounding and Preparation of Parenteral Solutions and Medications	\$59	SE AC M
3. Scope of Practice	S15	21. Medical Waste and		3
<ol> <li>Organization of Infusion and Vascular Access</li> </ol>	n	Sharps Safety	S60	3
Services	S23	SECTION FOUR:		3
<ol><li>Competency and Competency Assessment</li></ol>	S26	INFUSION EQUIPMENT	542	3
6. Quality Improvement	\$31	22. Vascular Visualization	303	3
<ol> <li>Evidence-Based Practic and Research</li> </ol>	e 534	Device Tip Location	S65	4
8. Patient Education	\$35	24. Flow-Control Devices	S69	4
9. Informed Consent	\$37	25. Blood and Fluid Warming	\$72	
10. Documentation in the Health Record	539	SECTION FIVE: VASCULAR ACCESS		4
SECTION TWO: PATIE	NT	DEVICE SELECTION AN	D	4
AND CLINICIAN SAFET	ΓY	FLACEMENT		4

26. Vascular Access Device

Planning

543

\$74

Contents

standard 27. Site Selection **S81** 28 Implanted Vascular \$86 Access Ports 9. Vascular Access and Hemodialysis \$89 30. Umbilical Catheters \$90 31. Vascular Access and Therapeutic Apheresis \$93 32. Pain Management for Venipuncture and Vascular Access Procedures \$94 33. Vascular Access Site Preparation and Skin Antisepsis \$96 34. Vascular Access Device \$97 Placement ECTION SIX: VASCULAR CCESS DEVICE ANAGEMENT 35. Filtration \$102 36. Needleless Connectors S104 37. Other Add-On Devices \$107 38. Vascular Access Device Securement S108 89. Joint Stabilization S111 10. Site Protection S112 41. Flushing and Locking S113 42. Vascular Access Device Assessment, Care, and Dressing Changes \$119 43. Administration Set \$123 Management 44. Blood Sampling **S125** 45. Vascular Access Device Removal \$133



# Catheter-associated urinary tract infections

# Outcome Burden

- Associated costs \$115 to 1.8 billion annually
- Most common cause of secondary BSI

# CAUTI Risk Factors Duration Immunosuppression Female gender Neurological disease Care and maintenance



## **RCA** Findings

- The most common contributing factors for CAUTI were comorbidities, lapses in catheter care protocols, active infection, fecal incontinence and duration of IUC.
- The duration of IUC was identified as a contributing factor for 16.5% of the CAUTI cases,
- Almost 25% of the cases reviewed the clinical teams and infection preventionists stated that the catheters could have been removed earlier.

Letica-Kriegel et al (2019)

## **CAUTI** Prevention Strategies

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY MAY 2014, VOL. 35, NO. 5

SHEA/IDSA PRACTICE RECOMMENDATION

#### Strategies to Prevent Catheter-Associated Urinary Tract Infections in Acute Care Hospitals: 2014 Update

Evelyn Lo, MD;<sup>1,4</sup> Lindsay E. Nicolle, MD;<sup>2,4</sup> Susan E. Coffin, MD, MPH;<sup>3</sup> Carolyn Gould, MD, MS;<sup>4</sup> Lisa L. Maragakis, MD, MPH;<sup>3</sup> lennifer Meddings, MD, MScs<sup>6</sup> David A. Pegues, MD;<sup>7</sup> Ann Marie Pettis, RN, BSN, ClC;<sup>6</sup> Sanjay Saint, MD, MPH;<sup>9</sup> Deborah S. Yokoe, MD, MPH<sup>10</sup>



#### GUIDELINE FOR PREVENTION OF CATHETER-ASSOCIATED URINARY TRACT INFECTIONS 2009

Carolyn V. Gould, MD, MSCR  $^1;$  Craig A. Umscheid, MD, MSCE  $^2;$  Rajender K. Agarwal, MD, MPH  $^3;$  Cretchen Kuntz, MSW, MSLIS  $^3;$  David A. Pegues, MD  $^3$  and the Healthcare Infection Control Practices Advisory Committee (HICPAC)  $^4$ 

<sup>1</sup> Division of Healthcare Quality Promotion Centers for Disease Control and Prevention Atlanta, GA

<sup>2</sup> Center for Evidence-based Practice University of Pennsylvania Health System Philadelphia, PA

<sup>3</sup> Division of Infectious Diseases David Geffen School of Medicine at UCLA Los Angeles, CA

Last update: June 6, 2019



Page 1 of 61

Guideline for Prevention of Catheter-Associated Urinary Tract Infections (2009) (cdc.gov)

## Indications for Urethral Catheter Use

#### Table 2.

#### A. Examples of Appropriate Indications for Indwelling Urethral Catheter Use 1-4

- Patient has acute urinary retention or bladder outlet obstruction.
- Need for accurate measurements of urinary output in critically ill patients.
- Perioperative use for selected surgical procedures:
  - Patients undergoing urologic surgery or other surgery on contiguous structures of the genitourinary tract.
  - Anticipated prolonged duration of surgery (catheters inserted for this reason should be removed in PACU).
  - o Patients anticipated to receive large-volume infusions or diuretics during surgery.
  - o Need for intraoperative monitoring of urinary output.
- To assist in healing of open sacral or perineal wounds in incontinent patients.
- Patient requires prolonged immobilization (e.g., potentially unstable thoracic or lumbar spine, multiple traumatic injuries such as pelvic fractures).
- To improve comfort for end of life care if needed.

#### B. Examples of Inappropriate Uses of Indwelling Catheters

- · As a substitute for nursing care of the patient or resident with incontinence.
- As a means of obtaining urine for culture or other diagnostic tests when the patient can voluntarily void.
- For prolonged postoperative duration without appropriate indications (e.g., structural repair of urethra or contiguous structures, prolonged effect of epidural anaesthesia, etc.).

Note: The above indications are based primarily on expert consensus.

Guideline for Prevention of Catheter-Associated Urinary Tract Infections (2009) (cdc.gov)



## **Real World Strategies**

Decreasing Catheter-Associated Urinary Tract Infection (CAUTI) at a community academic medical center using a multidisciplinary team employing a multi-pronged approach during the COVID-19 Pandemic



and the part	American Journal of Infection Control
Go to American Journ	al of Infection Control on ScienceDirect lable online 7 August 2022
ELSEVIER	In Press, Corrected Proof (?)

#### Practice forum

Decreasing Catheter-Associated Urinary Tract Infection (CAUTI) at a community academic medical center using a multidisciplinary team employing a multi-pronged approach during the COVID-19 pandemic

Amy Whitaker DO, MS, MBA 유 평, Gail Colgrove BS, RN, CIC, Maria Scheutzow BSN, RN, CIC, Meghan Ramic MSN, RN, Kim Monaco BSN, RN, James L Hill Jr. MD, MBA





acquired infections with a focus on catheter-associated urinary tract infection

#### METHODS

- Created a Multidisciplinary Team
- Closely monitored urinary catheters with daily morning meetings
- Created nursing driven removal protocol
- Educated nursing staff on nursing driven removal protocol
- Educate patients and families on hygiene
- ✓ Created indwelling urinary catheter insertion order set for electronic medical record
- Educated nursing staff and all medical providers on indwelling urinary catheter insertion order set
- Encourage external urinary diversion devices
- Created indwelling urinary catheter insertion checklist for bedside insertions
- Provided transparent feedback if CAUTI occurred

#### FINDINGS

- Downward trend CAUTI while nationally there was an upward trend.
- Decreased NHSN SIR for CAUTI was 0.37 in 2019, 0.23 in 2020, and 0.00 in 2021.
- Indwelling urinary catheter device usage lower than predicted number of device days per the NHSN Standardized Utilization Ratio.
- Increased use of external urinary diversion devices.

#### CONCLUSION

A collaborative approach decreasing hospital acquired infections may be effective even in a climate of increased acuity, increased length of stay, and staffing challenges.

Reference - Amy Whitaker et al (2022) Visual Abstract - Amy Whitaker DO. MS. MBA

# Alternatives to Indwelling Catheters

- Male and female external catheters
- Incontinence products
- Male and female urinals
- Bladder scanners
- Straight catheters

## Alternatives to the Indwelling Urinary Catheter







https://www.cdc.gov/infectioncontrol/pdf/strive/CA UTI103-508.pdf

## Calculating the Cost

### **CAUTI** Cost Calculator

ne CAUTI Cost Calculator estimates your hospital	s costs due to catheter-associated uninary tract infections (CAUTI), whic	n are the most common
ospital-acquired infection.		
t can be used to estimate both current costs and p	rojected costs after a hypothetical intervention to reduce catheter use,	a protocol that involves
issessment of the need for a catheter.		
Click on the image below to begin		
CALITI Cost Calculator		
Show Cost Calebrator		
Hospital inputs Number of annual adult hospital admissione	CURRENT ESTIMATED COSTS:	
1000	\$38,370	
Percentage of adult hospitalized paramits with indexeming univery catherine as any given day (3-100)	\$19,017	
	DEG FOTED CHURDO INTE OF	
Mean duration of urinary collectorization (in days)	\$19,352 (\$4,681 - \$80,010)	
Cost inputs		
Pergenson cost of symptomatic uninery tract infection (\$)	* Encode or an intervention with a 31% decrement in development and a 25% decrement is piccetwet;	
911		
Per person cost at bloodstream infection (2)		
Intervention inputs		
Percent decrease in callesterization duration caused by intervention (2-103		
37 B		
Percent decrease in urinary catheter placement caused by intervention (2-100)	and the second se	

https://www.catheterout.org/cauti-costcalculator.html

## Pneumonia (PNU)

- Pneumonia is most common HAI
  - Affects about 1 in 100 patients
    - up to 1 in 10 patients on mechanical ventilation
  - VAP attributable mortality approx. 10%
  - VAP and VAE Associated with increased:
    - LOS
    - mortality risk
    - Exposure to antimicrobials
    - Cost of care
  - NV-HAP is associated increased hospital stay and substantially higher mortality rates compared to similar patients without NV-HAP.

# **Prevention Strategies**

- Staff Education
- Surveillance
- Prevent transmission
  - Standard precautions
  - Equipment
- Modifying host risk factors
  - Vaccination
- Prevent aspiration

## **Pneumonia Prevention Strategies**

Infection Control & Hospital Epidemiology (2022), 43, 687-713 doi:10.1017/ice.2022.88

**SHEA** 

SHEA/IDSA/APIC Practice Recommendation

Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update

Michael Klompas MD, MPH<sup>1,2</sup> <sup>O</sup>, Richard Branson MSc, RRT<sup>3</sup> <sup>O</sup>, Kelly Cawcutt MD, MS<sup>4</sup> <sup>O</sup>, Matthew Crist MD<sup>5</sup> <sup>O</sup>, Eric C. Eichenwald MD<sup>5,7</sup>, Linda R. Greene RN, MPS, CIC<sup>6</sup>, Grace Lee MD<sup>9</sup>, Lisa L. Maragakis MD, MPH<sup>10</sup>, Krista Powell MD, MPH<sup>5</sup> <sup>O</sup>, Gregory P. Priebe MD<sup>11</sup> <sup>O</sup>, Kathleen Speck MPH<sup>12</sup>, Deborah S. Yokoe MD, MPH<sup>13</sup> and Sean M. Berenholtz MD, MHS<sup>12,4,4,5</sup>

<sup>10</sup>Pepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, <sup>20</sup>Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, <sup>10</sup>Department of Surgery, University of Chromstal Medicine, Circinnati, Uho, <sup>10</sup>Department of Medicine, University of Netskas Medical Center, Omaha, Netarasa, Pilokien od Healthere Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, <sup>10</sup>Department of Pediatrics, Children's Hospital of Philadelphia, Pentare, Rvairo Kr, <sup>10</sup>Strafford University School of Medicine, University of Pennsylvania, <sup>10</sup>Department of Medicine, Johns Hospita, University of Bochseter, Rochstere, Nev Tork, <sup>1</sup>Strafford University School of Medicine, California, <sup>10</sup>Department of Medicine, Johns Hospita, University O Rochseter, Rochstere, Nev Tork, <sup>1</sup>Strafford University School of Medicine, Pala Nito, <sup>10</sup>Department of Medicine, Johns Hospita, University School of Medicine, Baltimore, Maryland, <sup>10</sup>Department of Anesthesiology, Ortifical Care and Pain Medicine Anesthesiology and Critical Care Medicine, The Johns Hospitins University School of Medicine, Baltimore, Maryland, <sup>10</sup>Department of Medicine, Baltimore, Maryland, <sup>10</sup>Department of Medicine, Baltimore, Maryland, <sup>10</sup>Department of Anesthesiology and Critical Care Medicine, Chillorini, <sup>10</sup>Department of School of Medicine, Baltimore, Maryland, <sup>10</sup>Department of Medicine, Baltimore, Maryland and <sup>110</sup>Department of Medicine, Baltimore, Maryland and <sup>110</sup>Department of Medicine, Baltimore, Maryland

#### Abstract

The purpose of this document is to highlight practical recommendations to assist acute care hospitals to prioritize and implement strategies to prevent entithator-associated penemonia (VAP), ventilator-associated events (VAE), and non-ventilator hospital-acquired pneumonia (NV-HAP) in adults, children, and neonates. This document updates the Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals published in 2014. This expert guidance document is sponsored by the Society for Healthcare Epidemiology (SHEA), and is the product of a collaborative effort led by SHEA, the Infectious Diseases Society of America, the American Hospital Association, the Association for Professionals in Infection Control and Epidemiology, and The Joint Commission, with major contributions from representitives of a number of organizations and societies with content expertise.

(Received 21 March 2022; accepted 21 March 2022; electronically published 20 May 2022)

 Provide recommendations for adult, neonatal, and pediatric patients on mechanical ventilation

# Summary of Prevention of VAP/VAE Recommendations - Adult

#### **Essential Practices**

- Avoid intubation
- Minimize sedation
- Physical conditioning
- Elevate HOB 30-45
- Provide oral care- brushing
- Provide early enteral vs. parenteral nutrition
- Limit changing vent circuits

#### Additional Approaches

- Use selective oral or digestive decontamination in areas with low prevalence of antibiotic resistance
- Utilize ET tubes with subglottic secretion drainage ports
- Early tracheostomy
- Consider postplyoric rather than gastric in those at risk of aspiration

#### Generally, Not Recommended

- Oral care with CHG
- Probiotics
- Ultrathin polyurethane ET tube cuffs
- Tapered CT tube cuffs
- Frequent cuff-pressure monitoring
- Silver-coated ET Tube
- Kinetic beds
- Prone Positioning
- CHG Bathing
- Stress ulcer prophlyaxis
- Monitoring residual gastric volumes
- Early Parenteral nutrition
- Closed ET suctioning systems

## **IDSA** Guidelines

Clinical Infectious Diseases



## Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

Andre C. Kalil,<sup>1,a</sup> Mark L. Metersky<sup>2,a</sup> Michael Klompas,<sup>3,4</sup> John Muscedere,<sup>5</sup> Daniel A. Sweeney,<sup>6</sup> Lucy B. Palmer,<sup>7</sup> Lena M. Napolitano,<sup>8</sup> Naomi P. O'Grady,<sup>9</sup> John G. Bartlett,<sup>10</sup> Jordi Carratalà,<sup>11</sup> Ali A. El Solh,<sup>12</sup> Santiago Ewig,<sup>13</sup> Paul D. Fey,<sup>14</sup> Thomas M. File Jr,<sup>15</sup> Marcos I. Restrepo,<sup>16</sup> Jason A. Roberts,<sup>17,18</sup> Grant W. Waterer,<sup>19</sup> Peggy Cruse,<sup>20</sup> Shandra L. Knight,<sup>20</sup> and Jan L. Brozek<sup>21</sup>

<sup>1</sup>Department of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha; <sup>2</sup>Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, Farnington; <sup>3</sup>Brigham and Women's Hospital and Harvard Medical School, and <sup>4</sup>Harvard Pilgrim Health Care Institute, Boston, Massachusetts; <sup>3</sup>Department of Medicine, Critical Care Program, Queens University, Kingston, Ontario, Canada; <sup>6</sup>Division of Pulmonary, Critical Care and Sleep Medicine, University of Connecticut Division of Pulmonary Critical Care and Sleep Medicine, State University of New York at Stony Brook, <sup>6</sup>Department of Surgery, Division of Trauma, Critical Care and Emergency Surgery, University of Michigan, Ann Arbor, <sup>9</sup>Department of Critical Care Medicine, National Institutes of Health, Bethesda, and <sup>10</sup>Johns Hopkins University School of Medicine, Battimore, Maryland; <sup>11</sup>Department of Infectious Diseases, Hospital Universitari de Belivtige, Bellvitge Biomedical Research Institute, Spanish Network for Research in Infectious Diseases, University of Barcelona, Spain; <sup>12</sup>Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University at Buffalo, Veterans Affairs Western New York Healthcare System, New York; <sup>13</sup>Thoraxentrum Ruhrgebiet, Department of Respiratory and Infectious Diseases, EVK Herne and Augusta-Kranken-Anstalt Bochum, Germany, <sup>14</sup>Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha; <sup>16</sup>Summa Health System, Akron, Ohio; <sup>16</sup>Department of Medicine, Division of Pulmonary and Critical Care Medicine, South Texas Veterans Health Care System and University of Texas Health Science Center at San Antonio; <sup>17</sup>Burns, Trauma and Artical Care Research Center, The University of Queensland, <sup>16</sup>Royal Brisbane and Women's Hospital, Queensland, and <sup>10</sup>School of Medicine and Pharmacology, University of Western Australia; <sup>20</sup>Department of Canada

## **Preventing NV-HAP**

## Regular Oral Care

## Early mobilization

# Early diagnosis and treatment of dysphagia

# Implement interventions to prevent viral infections

• Symptom screening, universal masking when viral transmission rates are high, vaccination

## Bundles

• Oral hygiene, bed positioning, dysphagia diagnosis and management, mobilizing patients, nasal hygiene, sedation restrictions, incentive spirometry, education

## Role of Hand Hygiene

Figure



Figure. Overall healthcare-associated infection (HAI) rate and hand hygiene compliance by month, October 2013–February 2015. Numbers above data bar indicate monthly compliance percentages. Error bars indicate 95% Cls.

Sickbert-Bennett EE, DiBiase LM, Willis TM, Wolak ES, Weber DJ, Rutala WA. Reduction of Healthcare-Associated Infections by Exceeding High Compliance with Hand Hygiene Practices. Emerg Infect Dis. 2016;22(9):1628-1630. https://doi.org/10.3201/eid2209.151440

- Higher is better
  - High compliance with hand hygiene necessary
- Don't lose focus
  - Continuous improvement is critical





## **Closing** Thoughts

- Avoid use of invasive devices where possible
- Clearly identify the rational for the device
- Daily assessment of device necessity
- Also need to consider impact of non-targeted HAI
  - PIV infections
  - UTI
  - PNU

## Thanks!

- Discussion
  - How has the pandemic impacted best practices around HAI prevention?
  - What barriers/ or successes have you encountered implementing HAI reduction interventions?

CNE: You will receive an email from me with information on how to get your credit.

Website: Nuggets of Knowledge

Next Session: November 10 at 1pm
 Managing the Flow

THANK YOU!!

## **Reference** List

- Marin-Corral, J., Pascual-Guardia, S., Muñoz-Bermúdez, R., Salazar-Degracia, A., Climent, C., Vilà-Vilardell, C., ... & Álvarez-Lerma, F. (2022). Health care-associated infections in patients with COVID-19 pneumonia in COVID critical care areas. Medicina intensiva, 46(4), 221.
- Baccolini, V., Migliara, G., Isonne, C., Dorelli, B., Barone, L. C., Giannini, D., ... & Villari, P. (2021). The impact of the COVID-19 pandemic on healthcare-associated infections in intensive care unit patients: a retrospective cohort study. Antimicrobial Resistance & Infection Control, 10(1), 1-9.
- Lastinger, L. M., Alvarez, C. R., Kofman, A., Konnor, R. Y., Kuhar, D. T., Nkwata, A., ... & Dudeck, M. A. (2022). Continued Increases in HAI Incidence During the Second Year of the COVID-19 Pandemic. Infection Control & Hospital Epidemiology, 1-19.
- Weiner-Lastinger, L., Pattabiraman, V., Konnor, R., Patel, P., Wong, E., Xu, S., . . . Dudeck, M. (2022). The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: A summary of data reported to the National Healthcare Safety Network. Infection Control & Hospital Epidemiology, 43(1), 12-25. doi:10.1017/ice.2021.362
- Fakih, M., Bufalino, A., Sturm, L., Huang, R., Ottenbacher, A., Saake, K., . . . Cacchione, J. (2022). Coronavirus disease 2019 (COVID-19) pandemic, central-line–associated bloodstream infection (CLABSI), and catheter-associated urinary tract infection (CAUTI): The urgent need to refocus on hardwiring prevention efforts. Infection Control & Hospital Epidemiology, 43(1), 26-31. doi:10.1017/ice.2021.70
- CDC (2021). 2020 National and State Healthcare-Associated Infections Progress Report. Retrieved from https://www.cdc.gov/hai/data/portal/progress-report.html
- Werneburg GT. Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects. Res Rep Urol. 2022 Apr 4;14:109-133. doi: 10.2147/RRU.S273663. PMID: 35402319; PMCID: PMC8992741.